Published in PLoS Negl Trop Dis on September 14, 2010
Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease. Cochrane Database Syst Rev (2014) 1.35
Comparative study of rK39 Leishmania antigen for serodiagnosis of visceral leishmaniasis: systematic review with meta-analysis. PLoS Negl Trop Dis (2012) 1.26
Leishmaniasis: new insights from an old and neglected disease. Eur J Clin Microbiol Infect Dis (2011) 1.17
The development and clinical evaluation of second-generation leishmaniasis vaccines. Vaccine (2011) 1.03
Comparison of visceral leishmaniasis diagnostic antigens in African and Asian Leishmania donovani reveals extensive diversity and region-specific polymorphisms. PLoS Negl Trop Dis (2013) 0.99
Biomarkers for intracellular pathogens: establishing tools as vaccine and therapeutic endpoints for visceral leishmaniasis. Clin Microbiol Infect (2013) 0.94
Evaluation of rK28 antigen for serodiagnosis of visceral Leishmaniasis in India. Clin Microbiol Infect (2011) 0.93
rKLO8, a novel Leishmania donovani - derived recombinant immunodominant protein for sensitive detection of visceral leishmaniasis in Sudan. PLoS Negl Trop Dis (2013) 0.91
Significantly lower anti-Leishmania IgG responses in Sudanese versus Indian visceral leishmaniasis. PLoS Negl Trop Dis (2014) 0.89
Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasis. Eur J Clin Microbiol Infect Dis (2014) 0.84
Heterogeneity of Leishmania donovani parasites complicates diagnosis of visceral leishmaniasis: comparison of different serological tests in three endemic regions. PLoS One (2015) 0.83
Polymorphism in the HASPB repeat region of East African Leishmania donovani strains. PLoS Negl Trop Dis (2013) 0.82
Alteration of the serum biomarker profiles of visceral leishmaniasis during treatment. Eur J Clin Microbiol Infect Dis (2013) 0.81
Accurate Serodetection of Asymptomatic Leishmania donovani Infection by Use of Defined Antigens. J Clin Microbiol (2016) 0.79
IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid diagnostic test. PLoS Negl Trop Dis (2014) 0.78
Comparison of point-of-care tests for the rapid diagnosis of visceral leishmaniasis in East African patients. Am J Trop Med Hyg (2014) 0.77
Developments in Diagnosis of Visceral Leishmaniasis in the Elimination Era. J Parasitol Res (2015) 0.77
Evaluation of diagnostic performance of rK28 ELISA using urine for diagnosis of visceral leishmaniasis. Parasit Vectors (2016) 0.76
Identification and Characterization of a Novel, 37-Kilodalton Leishmania donovani antigen for diagnosis of Indian visceral leishmaniasis. Clin Vaccine Immunol (2011) 0.76
Local Production of a Liquid Direct Agglutination Test as a Sustainable Measure for Control of Visceral Leishmaniasis in Sudan. Am J Trop Med Hyg (2016) 0.75
Cloning, Expression and Purification of L. Donovani Specific Antigen for Serodiagnosis of Visceral Leishmaniasis. J Mol Biomark Diagn (2013) 0.75
An rK28-Based Immunoenzymatic Assay for the Diagnosis of Canine Visceral Leishmaniasis in Latin America. Am J Trop Med Hyg (2016) 0.75
Noninvasive Diagnosis of Visceral Leishmaniasis: Development and Evaluation of Two Urine-Based Immunoassays for Detection of Leishmania donovani Infection in India. PLoS Negl Trop Dis (2016) 0.75
Systematic review of biomarkers to monitor therapeutic response in leishmaniasis. Antimicrob Agents Chemother (2014) 0.75
Application of Recombinant Proteins for Serodiagnosis of Visceral Leishmaniasis in Humans and Dogs. Iran Biomed J (2016) 0.75
Diagnostic antigens for visceral leishmaniasis: clarification of nomenclatures. Parasit Vectors (2017) 0.75
Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem (1993) 27.24
Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet (1998) 3.55
Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci U S A (1993) 3.40
rK39: a cloned antigen of Leishmania chagasi that predicts active visceral leishmaniasis. J Infect Dis (1996) 2.93
Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg (2007) 2.53
A simple and economical direct agglutination test for serodiagnosis and sero-epidemiological studies of visceral leishmaniasis. Trans R Soc Trop Med Hyg (1986) 2.21
Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan. Trop Med Int Health (2001) 2.08
Quantifying the information value of clinical assessments with signal detection theory. Annu Rev Psychol (1999) 1.95
Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol (2006) 1.75
Diagnostic accuracy of two rK39 antigen-based dipsticks and the formol gel test for rapid diagnosis of visceral leishmaniasis in northeastern Uganda. J Clin Microbiol (2005) 1.67
Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi. Mol Biochem Parasitol (1999) 1.38
Identification and synthesis of a major conserved antigenic epitope of Trypanosoma cruzi. Proc Natl Acad Sci U S A (1992) 1.34
Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex. Infect Immun (2006) 1.27
Leishmania-host-cell interaction: complexities and alternative views. Parasitol Today (2000) 1.23
Immunological dominance of Trypanosoma cruzi tandem repeat proteins. Infect Immun (2008) 1.18
Fundamental measures of diagnostic examination performance: usefulness for clinical decision making and research. Radiology (2003) 1.15
Comparative evaluation of direct agglutination test, rK39 and soluble antigen ELISA and IFAT for the diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2007) 1.11
Development of recombinant chimeric antigen expressing immunodominant B epitopes of Leishmania infantum for serodiagnosis of visceral leishmaniasis. Clin Diagn Lab Immunol (2005) 1.09
Cloning, characterization, and serodiagnostic evaluation of Leishmania infantum tandem repeat proteins. Infect Immun (2006) 1.09
Expression of hydrophilic surface proteins in infective stages of Leishmania donovani. Mol Biochem Parasitol (1999) 1.08
Diversity in repeat-containing surface proteins of Leishmania major. Mol Biochem Parasitol (1997) 1.01
Upregulated expression of B-cell antigen family tandem repeat proteins by Leishmania amastigotes. Infect Immun (2010) 0.95
Prokaryotic expression and antigenic characterization of three recombinant Leishmania antigens for serological diagnosis of canine leishmaniasis. Clin Diagn Lab Immunol (2003) 0.95
Molecular dissection and expression of the LdK39 kinesin in the human pathogen, Leishmania donovani. Mol Microbiol (2007) 0.89
Validation of a recombinant based antibody ELISA for diagnosis of human and canine leishmaniasis. J Immunoassay Immunochem (2008) 0.83
Development of a normal human immunoglobulin G standard curve for enzyme-linked immunosorbent assay: use for comparison of antigen efficacy. J Immunoassay Immunochem (2006) 0.81
Trans-acting regulatory variation in Saccharomyces cerevisiae and the role of transcription factors. Nat Genet (2003) 11.84
Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med (2007) 11.80
Genetic interactions between polymorphisms that affect gene expression in yeast. Nature (2005) 6.42
Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest (2004) 5.39
Local regulatory variation in Saccharomyces cerevisiae. PLoS Genet (2005) 3.23
Simultaneous genotyping, gene-expression measurement, and detection of allele-specific expression with oligonucleotide arrays. Genome Res (2005) 2.66
Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol (2004) 2.56
Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One (2011) 2.39
Prospective case-control study of the association between common enteric protozoal parasites and diarrhea in Bangladesh. Clin Infect Dis (2009) 2.35
Multiplex real-time PCR assay for detection of Entamoeba histolytica, Giardia intestinalis, and Cryptosporidium spp. Am J Trop Med Hyg (2007) 2.29
Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis (2011) 2.19
Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev (2011) 2.09
Real-time-PCR assay for diagnosis of Entamoeba histolytica infection. J Clin Microbiol (2005) 2.06
Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol (2002) 2.05
A paper-based multiplexed transaminase test for low-cost, point-of-care liver function testing. Sci Transl Med (2012) 2.05
A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med (2010) 2.00
Second-generation vaccines against leishmaniasis. Trends Parasitol (2005) 1.99
Entamoeba histolytica infection in children and protection from subsequent amebiasis. Infect Immun (2006) 1.99
Malaria prevalence in endemic districts of Bangladesh. PLoS One (2009) 1.93
Epidemiologic and clinical characteristics of acute diarrhea with emphasis on Entamoeba histolytica infections in preschool children in an urban slum of Dhaka, Bangladesh. Am J Trop Med Hyg (2003) 1.92
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun (2004) 1.90
Effects of in utero arsenic exposure on child immunity and morbidity in rural Bangladesh. Toxicol Lett (2009) 1.89
Propionibacterium acnes types I and II represent phylogenetically distinct groups. J Clin Microbiol (2005) 1.75
Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal. Am J Trop Med Hyg (2010) 1.74
Identification of human T cell antigens for the development of vaccines against Mycobacterium tuberculosis. J Immunol (2008) 1.70
Diagnosis of amebic liver abscess and amebic colitis by detection of Entamoeba histolytica DNA in blood, urine, and saliva by a real-time PCR assay. J Clin Microbiol (2010) 1.70
Giardia assemblage A infection and diarrhea in Bangladesh. J Infect Dis (2005) 1.70
Innate and acquired resistance to amebiasis in bangladeshi children. J Infect Dis (2002) 1.68
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis (2012) 1.62
Enhanced humoral and Type 1 cellular immune responses with Fluzone adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine (2009) 1.60
A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis (2012) 1.59
Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment. Trop Med Int Health (2008) 1.59
Intradermal immunization improves protective efficacy of a novel TB vaccine candidate. Vaccine (2009) 1.58
A synthetic adjuvant to enhance and expand immune responses to influenza vaccines. PLoS One (2010) 1.57
Chagas' disease diagnosis: a multicentric evaluation of Chagas Stat-Pak, a rapid immunochromatographic assay with recombinant proteins of Trypanosoma cruzi. Diagn Microbiol Infect Dis (2003) 1.55
A mutation in the leptin receptor is associated with Entamoeba histolytica infection in children. J Clin Invest (2011) 1.55
Use of multiepitope polyproteins in serodiagnosis of active tuberculosis. Clin Diagn Lab Immunol (2002) 1.54
Targeting TLRs expands the antibody repertoire in response to a malaria vaccine. Sci Transl Med (2011) 1.53
Novel point-of-care test for simultaneous detection of nontreponemal and treponemal antibodies in patients with syphilis. J Clin Microbiol (2010) 1.52
MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. Cancer Biol Ther (2008) 1.51
Adjuvants for cancer vaccines. Semin Immunol (2010) 1.48
Identification of concomitant infection with Chlamydia trachomatis IncA-negative mutant and wild-type strains by genomic, transcriptional, and biological characterizations. Infect Immun (2008) 1.48
C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann Neurol (2007) 1.47
Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces (2009) 1.47
Improved serodetection of Mycobacterium bovis infection in badgers (Meles meles) using multiantigen test formats. Diagn Microbiol Infect Dis (2003) 1.45
Use of protein antigens for early serological diagnosis of leprosy. Clin Vaccine Immunol (2007) 1.45
Tuberculosis in elephants: antibody responses to defined antigens of Mycobacterium tuberculosis, potential for early diagnosis, and monitoring of treatment. Clin Vaccine Immunol (2006) 1.44
The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection. Am J Trop Med Hyg (2002) 1.43
MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J (2006) 1.42
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun (2002) 1.42
Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS Negl Trop Dis (2011) 1.42
Validation of a rapid and reliable test for diagnosis of chagas' disease by detection of Trypanosoma cruzi-specific antibodies in blood of donors and patients in Central America. J Clin Microbiol (2005) 1.41
The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol (2012) 1.39
Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine (2009) 1.39
A novel cardiac positioning device for left main coronary artery stenosis. Ann Thorac Surg (2012) 1.38
Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun (2007) 1.34
Influence of human leukocyte antigen class II alleles on susceptibility to Entamoeba histolytica infection in Bangladeshi children. J Infect Dis (2004) 1.31
CAMP factor homologues in Propionibacterium acnes: a new protein family differentially expressed by types I and II. Microbiology (2005) 1.28
Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine (2002) 1.28
Bioinformatic identification of tandem repeat antigens of the Leishmania donovani complex. Infect Immun (2006) 1.27
Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun (2005) 1.26
Highly accurate antibody assays for early and rapid detection of tuberculosis in African and Asian elephants. Clin Vaccine Immunol (2009) 1.26
Adjuvants for human vaccines. Curr Opin Immunol (2012) 1.25
Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis. J Control Release (2013) 1.25
Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun (2006) 1.23
GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. J Infect Dis (2011) 1.22
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140. PLoS One (2012) 1.22
Leishmania model for microbial virulence: the relevance of parasite multiplication and pathoantigenicity. Acta Trop (2003) 1.20
Case study for a vaccine against leishmaniasis. Vaccine (2013) 1.19
Identification of Mycobacterium tuberculosis antigens of high serodiagnostic value. Clin Vaccine Immunol (2010) 1.19
Immunological dominance of Trypanosoma cruzi tandem repeat proteins. Infect Immun (2008) 1.18
Serologic tests for detecting antibodies against Mycobacterium bovis and Mycobacterium avium subspecies paratuberculosis in Eurasian wild boar (Sus scrofa scrofa). J Vet Diagn Invest (2011) 1.18
Correlation of interferon-gamma production by peripheral blood mononuclear cells with childhood malnutrition and susceptibility to amebiasis. Am J Trop Med Hyg (2007) 1.17
Malnutrition and helminth infection affect performance of an interferon gamma-release assay. Pediatrics (2010) 1.17
Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry (2002) 1.16
Comparison of two immunochromatographic assays and the indirect immunofluorescence antibody test for diagnosis of Trypanosoma cruzi infection in dogs in south central Louisiana. Vet Parasitol (2009) 1.16
Evaluation of Entamoeba histolytica antigen and antibody point-of-care tests for the rapid diagnosis of amebiasis. J Clin Microbiol (2006) 1.16
A major susceptibility locus on chromosome 22q12 plays a critical role in the control of kala-azar. Am J Hum Genet (2003) 1.14
Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci U S A (2012) 1.14
A simplified and standardized polymerase chain reaction format for the diagnosis of leishmaniasis. J Infect Dis (2008) 1.14
Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol (2010) 1.14
Potential serological use of a recombinant protein that is a replica of a Mycobacterium tuberculosis protein found in the urine of infected mice. Clin Diagn Lab Immunol (2004) 1.13
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine (2011) 1.13
Immunotherapy for drug-refractory mucosal leishmaniasis. J Infect Dis (2006) 1.12
Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis. Vaccine (2009) 1.12
Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants. Subcell Biochem (2010) 1.12
ML0405 and ML2331 are antigens of Mycobacterium leprae with potential for diagnosis of leprosy. Clin Vaccine Immunol (2006) 1.11
PrimaTB STAT-PAK assay, a novel, rapid lateral-flow test for tuberculosis in nonhuman primates. Clin Vaccine Immunol (2007) 1.11
Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int J Parasitol (2011) 1.10